US Drug Recall Register
Class II · Moderate risk Terminated Initiated May 28, 2015 (11 years ago)

GENTAMICIN 14.4 mg / NS 30 mL SYRINGE

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Sterility of product is not assured.

What was recalled

GENTAMICIN 14.4 mg / NS 30 mL SYRINGE, Packaged in 30 mL Syringes, Rx Only. Compounded by: United Medical IV Center (Little Rock) 1527 South Bowman Rd. Ste. D Little Rock, AR 72211-4200.

Recalling firm
Lincare, Inc.
Origin
AR, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1195-2015

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Gentamicin recalls

See all
Class II · Moderate risk Ongoing

Gentamicin Injection

Reason Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Eugia US LLC NDC 55150-401-01 D-0472-2025
Class II · Moderate risk Terminated

Gentamicin Bladder 0.08mg/Ml

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0209-2023
Class II · Moderate risk Terminated

Gentamicin Sulfate Cream USP

Reason cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Teligent Pharma, Inc. NDC 70512-036-30 D-0702-2022
Class II · Moderate risk Terminated

Gentamicin Sulfate Ointment USP 0.1%

Reason cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Teligent Pharma, Inc. NDC 52565-090-15 D-0687-2022
Class II · Moderate risk Terminated

Gentamicin Sulfate Cream USP

Reason cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.

Teligent Pharma, Inc. NDC 52565-085-15 D-0686-2022